Hematologic Malignancy Applications

Hematologic Malignancy Applications is a scholarly contribution in the field of oncology that specifically denotes the therapeutic use of bispecific antibodies to target hematologic malignancies, distinguished by its focus on leveraging dual-binding specificity to redirect immune effector cells against malignant cells in blood cancers.

174

Publications

11.7K

Citations

1.7K

Authors

527

Institutions

Publications per year

2017–2026

81

Authors

1.7K

  1. HM
    Hagop M. Kantarjian

    The University of Texas MD Anderson Cancer Center, United States

    8 publications · 907 citations

    8

    h-index

  2. DA
    David A. Sallman

    Moffitt Cancer Center, United States

    6 publications · 383 citations

    6

    h-index

  3. ND
    Naval Daver

    The University of Texas MD Anderson Cancer Center, United States

    5 publications · 367 citations

    5

    h-index

  4. OW
    Oliver W. Press

    Fred Hutch Cancer Center, United States

    4 publications · 162 citations

    4

    h-index

  5. AS
    Anjali S. Advani

    Cleveland Clinic, United States

    4 publications · 506 citations

    4

    h-index

1–5 of 1.7K

Venues

  1. Blood

    24 publications · 2.7K citations

    19

    h-index

  2. PubMed

    Repository · 14 publications · 664 citations

    13

    h-index

  3. Journal of Clinical Oncology

    7 publications · 502 citations

    7

    h-index

  4. Leukemia

    6 publications · 834 citations

    6

    h-index

  5. Cancer Research

    6 publications · 179 citations

    6

    h-index

1–5